Expected Impact
Building the Foundation for Immune Cell Gene Therapies through Advanced CAR-T, TCR-T, and TIL Technologies for Solid Tumors
- Building an Integrated R&D Ecosystem
- Establishing a collaborative research network across academia, industry, research institutes, and hospitals, encompassing clinical research, clinical-grade viral vector production, and cell manufacturing for CAR-T, TCR-T, and TIL therapies.
- Establishing a National Cancer Database
- Building a centralized repository integrating neoantigen immunogenicity, infused cell characterization, and clinical therapeutic response data at the National Cancer Data Center.
Reducing the Economic Burden of Cancer Care through Regenerative Medicine
- Strengthening National Competitiveness through Clinical Research
- Building a clinical research foundation for CAR-T, TCR-T, and TIL therapies to accelerate commercialization and strengthen intellectual property.
- Reducing the Economic Burden of Cancer Treatment
- Advancing innovative, locally developed cancer therapies to improve patient access and help reduce the economic burden of cancer treatment.